Jiangsu Kanion Receives NMPA Approval for KYS2301 Gel in Atopic Dermatitis Clinical Study
CompanyDrug

Jiangsu Kanion Receives NMPA Approval for KYS2301 Gel in Atopic Dermatitis Clinical Study

Sino Biopharmaceutical's Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment
CompanyDrug

Sino Biopharmaceutical’s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment

Thermo Fisher's Oncomine Dx Express Test Approved by FDA as Companion Diagnostic for Dizal's Zegfrovy
CompanyMedical Device

Thermo Fisher’s Oncomine Dx Express Test Approved by FDA as Companion Diagnostic for Dizal’s Zegfrovy

Jiangsu Hengrui Announces NMPA Approval for Miebo in Dry Eye Disease Treatment
CompanyDrug

Jiangsu Hengrui Announces NMPA Approval for Miebo in Dry Eye Disease Treatment

China's WeiMai Plans Hong Kong IPO to Expand AI-Powered Healthcare Services
CompanyDeals

China’s WeiMai Plans Hong Kong IPO to Expand AI-Powered Healthcare Services

MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension
CompanyDrug

MSD’s Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension

Hangzhou Jiuyuan Announces NMPA Approval for Generic Doptelet in Thrombocytopenia Treatment
CompanyDrug

Hangzhou Jiuyuan Announces NMPA Approval for Generic Doptelet in Thrombocytopenia Treatmen

Betta Pharmaceuticals' Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment
CompanyDrug

Betta Pharmaceuticals’ Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment

BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections
CompanyDeals

BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections

Regeneron's Lynozyfic Granted FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
CompanyDrug

Regeneron’s Lynozyfic Granted FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma

Sumitomo Pharma's Xenleta Approved in China for Community-Acquired Pneumonia Treatment
CompanyDrug

Sumitomo Pharma’s Xenleta Approved in China for Community-Acquired Pneumonia Treatment

BEBT-908 Receives Conditional NMPA Approval for Relapsed/Refractory DLBCL
CompanyDrug

BEBT-908 Receives Conditional NMPA Approval for Relapsed/Refractory DLBCL